Nonvalvular Atrial Fibrillation

The FDA has approved a second-generation left atrial appendage closure device for patients with nonvalvular atrial fibrillation, Boston Scientific announced.

Patients with nonvalvular atrial fibrillation and normal kidney function had increased bleeding risk with dabigatran when used alongside P-glycoprotein inhibitors diltiazem and verapamil, according to a retrospective comparative effectiveness cohort study published in JAMA Network Open.

A meta-analysis of randomized controlled trials published in the Annals of Internal Medicine showed that dual therapy was associated with lower risk for major bleeding in patients with nonvalvular atrial fibrillation after PCI compared with triple therapy.

In an observational study of real-world patients with nonvalvular atrial fibrillation, those treated with rivaroxaban had a significant risk reduction for severe stroke and all-cause mortality after stroke compared with patients who were prescribed warfarin, according to research published in Stroke.

Rates of stroke at 4 years were low for patients with nonvalvular atrial fibrillation who underwent left atrial appendage, or LAA, closure with an FDA-approved device, according to new registry data.

Healio and Cardiology Today present a list of the most-viewed cardiology articles in December. This month, our readers were most interested in benefits of intermittent fasting, the effect of chili pepper consumption on the heart, oral hygiene and CV health, the FDA approval of apixaban generics and more.

The FDA announced it approved two applications for the first generic versions of apixaban tablets to reduce risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

PARIS — In patients with atrial fibrillation who underwent PCI, an antithrombotic strategy of edoxaban plus a P2Y12 inhibitor was noninferior to a vitamin K antagonist-based triple regimen for bleeding, with no significant differences in ischemic events.